4 results
RAD1901, a novel selective ER modulator (SERM)/selective ER degrader (SERD), has previously been demonstrated to modulate the ER in both nonclinical and clinical studies. The aim of this study is to visualise and quantify ER-binding sites during…
Primary ObjectivesIn patients with primary hypercholesterolemia and high cardiovascular risk with LDL-C >=100 mg/dL (2.59 mmol/L) and <=160 mg/dL (4.14 mmol/L), to evaluate:1)at the end of Phase I, the additional LDL-C percentage…
Primary objective:To compare the efficacy of iberdomide, daratumumab and dexamethasone (IberDd) to that of daratumumab, bortezomib and dexamethasone (DVd) in terms of progression-free survival (PFS) in subjects with RRMMSecondary objectives:• In…
Primary objective: To evaluate progression-free survival